Advertisement
Editorial| Volume 22, ISSUE 1, P3-4, January 2023

Early Glucose abnormalities in cystic fibrosis – how best to measure them, and what is to be done about them?

  • Dr Shihab Hameed
    Affiliations
    Department of Paediatric Endocrinology, Sydney Children's Hospital, Randwick, New South Wales AUSTRALIA

    Department of Paediatric Endocrinology and Diabetes Royal North Shore Hospital, St.Leonards, New South Wales, AUSTRALIA

    School of Women's and Children's Health, University of New South Wales, Kensington New South Wales, AUSTRALIA

    Northern Clinical School, University of Sydney, St.Leonards, New South Wales, AUSTRALIA
    Search for articles by this author
      In recent decades, two concepts have grown to increasing prominence in the field of cystic fibrosis related diabetes (CFRD). The first notion is that glucose abnormalities can be detected well before the diagnosis of CFRD can be made using current diagnostic criteria. The second concept is that it is biologically plausible that these glucose abnormalities may be of clinical importance to people with cystic fibrosis (via mechanisms that include increasing glucose in airway secretions [
      • Brennan AL
      • Gyi KM
      • Wood DM
      • Johnson J
      • Holliman R
      • Baines DL
      • et al.
      Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis.
      ], thereby promoting respiratory infections, as well as through catabolism from reduced secretion of insulin, a potent anabolic hormone [
      • Ripa P
      • Robertson I
      • Cowley D
      • Harris M
      • Masters IB
      • Cotterill AM.
      The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis.
      ]. However, as these concepts have gained increasing acceptance, they have prompted further questions which presently remain unanswered.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brennan AL
        • Gyi KM
        • Wood DM
        • Johnson J
        • Holliman R
        • Baines DL
        • et al.
        Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis.
        J Cyst Fibros. 2007; 6: 101-109
        • Ripa P
        • Robertson I
        • Cowley D
        • Harris M
        • Masters IB
        • Cotterill AM.
        The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis.
        Clin Endocrinol (Oxf). 2002; 56: 383-389
        • Lanng S
        • Hansen A
        • Thorsteinsson B
        • Nerup J
        • Koch C.
        Glucose tolerance in patients with cystic fibrosis: five year prospective study.
        BMJ. 1995; 311: 655-659
        • Ode KL
        • Ballman M
        • Battezzati A
        • Brennan A
        • Chan CL
        • Hameed S
        • et al.
        ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.
        Pediatr Diabetes. 2022; 23: 1212-1228
        • Prentice BJ
        • Jaffe A
        • Hameed S
        • Verge CF
        • Waters S
        • Widger J.
        Cystic fibrosis-related diabetes and lung disease: an update.
        Eur Respir Rev. 2021; 30
      1. Hameed S, Robinson P. Cystic fibrosis-related diabetes mellitus. 2023. In: UpToDate [Internet]. Available from: https://www.uptodate.com/contents/cystic-fibrosis-related-diabetes-mellitus.

        • Bennett PH
        • Burch TA
        • Miller M.
        Diabetes mellitus in American (Pima) Indians.
        Lancet. 1971; 2: 125-128
        • Hameed S
        • Morton JR
        • Jaffe A
        • Field PI
        • Belessis Y
        • Yoong T
        • et al.
        Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain.
        Diabetes Care. 2010; 33: 221-226
        • Dobson L
        • Sheldon CD
        Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients.
        Diabet Med. 2004; 21: 691-696
        • Potter KJ
        • Boudreau V
        • Bonhoure A
        • Tremblay F
        • Lavoie A
        • Carricart M
        • et al.
        Insulinogenic index and early phase insulin secretion predict increased risk of worsening glucose tolerance and of cystic fibrosis-related diabetes.
        Journal of Cystic Fibrosis. 2023;
      2. Patient Registry Annual Data Report. 2021.

        • Chan CL
        • Ode KL
        • Granados A
        • Moheet A
        • Moran A
        • Hameed S.
        Continuous glucose monitoring in cystic fibrosis - A practical guide.
        J Cyst Fibros. 2019; 18: S25-S31
        • Kumar S
        • Soldatos G
        • Ranasinha S
        • Teede H
        • Pallin M.
        Continuous glucose monitoring versus self-monitoring of blood glucose in the management of Cystic Fibrosis Related Diabetes; a systematic review and meta-analysis.
        Journal of Cystic Fibrosis. 2023;
        • Beck RW
        • Riddlesworth T
        • Ruedy K
        • Ahmann A
        • Bergenstal R
        • Haller S
        • et al.
        Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
        JAMA. 2017; 317: 371-378
        • Polonsky WH
        • Hessler D
        • Ruedy KJ
        • Beck RW
        • Group DS.
        The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial.
        Diabetes Care. 2017; 40: 736-741
        • Sandy JL
        • Nyunt O
        • Woodhead HJ
        • Youde LS
        • Ramjan KA
        • Jack MM
        • et al.
        Sydney Diabetes centre's experience of the Australian Government's roll out of subsidised continuous glucose monitoring for children with type 1 diabetes mellitus.
        J Paediatr Child Health. 2019; 55: 1056-1062
        • Rasouli N
        • Seggelke S
        • Gibbs J
        • Hawkins RM
        • Casciano ML
        • Cohlmia E
        • et al.
        Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions.
        J Diabetes Sci Technol. 2012; 6: 1038-1044
        • Scheuing N
        • Badenhoop K
        • Borkenstein M
        • Konrad K
        • Lilienthal E
        • Laubner K
        • et al.
        Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes?.
        Pediatr Diabetes. 2015; 16: 10-15
        • Pallin M
        • Kumar S
        • Daley C
        • Dawadi S
        • Leong P
        • Carr E
        • et al.
        Continuous glucose monitoring indices predict poor FEV(1) recovery following cystic fibrosis pulmonary exacerbations.
        J Cyst Fibros. 2021; 20: 785-791
        • Declercq D
        • Helleputte S
        • Marchand S
        • Van Aken S
        • Van Braeckel E
        • van Daele S
        • et al.
        Glycemic indices at night measured by CGM are predictive for a lower pulmonary function in adults but not in children with cystic fibrosis.
        Journal of Cystic Fibrosis. 2023;
        • Prentice BJ
        • Ooi CY
        • Verge CF
        • Hameed S
        • Widger J.
        Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis.
        J Cyst Fibros. 2020; 19: 700-703

      Linked Article